Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.

There has been a great deal of recent work that has used the combination of plasmapheresis and intravenous immunoglobulin (IVIG) to treat humoral rejection. It seems to be an important advance.

Long-term graft survival requires lifelong immunosuppression, but noncompliance is high among renal transplant recipients. 'Swinging' between underdosing and overdosing of medication causes high ...

IN recent months it has become increasingly evident that humoral antibodies as well as cellular immune mechanisms sometimes play an active part in the rejection of human kidney transplants. Several ...